Sword Health vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital physical therapy platform. $4B valuation. $240M ARR, cash-flow positive. 2,500+ employers. Founded 2015, Porto/NYC. Raised $340M+. Private.
About
Sword Health is a digital musculoskeletal care company founded in 2015 and headquartered in New York City with engineering roots in Porto, Portugal. The company was founded by physical therapist and engineer Virgílio Bento with the mission of freeing two billion people from pain using AI-powered physical therapy that matches or exceeds the clinical outcomes of in-person care. Sword pioneered the use of sensor-equipped motion trackers combined with AI therapy guidance delivered through a tablet interface.\n\nSword's platform pairs each member with a licensed physical therapist who designs and supervises a personalized program, while an AI engine called Phoenix handles real-time biomechanical coaching during sessions, monitors adherence, and flags clinical concerns for human review. Programs cover the full MSK spectrum — back, neck, shoulder, hip, knee, and post-surgical rehabilitation — as well as pelvic health through its Bloom product. Sword sells to self-insured employers and health plans; it has contracted with more than 2,500 enterprise customers including major Fortune 500 companies.\n\nSword reached $240 million in annualized recurring revenue and achieved cash-flow positivity, a rare milestone among digital health companies at its stage. The company has raised more than $340 million in total funding, reaching a $4 billion valuation. Its clinical evidence base — spanning dozens of peer-reviewed studies demonstrating meaningful pain reduction and return-to-work rates — differentiates Sword in a crowded MSK market and supports its position as the leading AI-native physical therapy platform.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.